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Oligomycins are a group of 26 macrocyclic lactones that exhibit broad biological activities, including antifungal, anticancer and 
nematocidal activities. Analysis of the oligomycin biosynthetic gene cluster (olm) in S. avermitilis revealed 2 tandem LuxR-type 
regulators, OlmRI (931 aa) and OlmRII (941 aa), with shared identity of 38%. Gene replacement of olmRI or olmRII abolished 
oligomycin production, and this production could be partially restored in the disruptants by introducing cloned olmRI and olmRII 
with their native promoters, demonstrating the essential role of OlmRI and OlmRII for oligomycin biosynthesis. Quantitative 
real-time RT-PCR analysis revealed that transcription of 14 olm genes was differentially affected by the deletion of olmRI and 
olmRII. Unexpectedly, avermectin production in both mutants was enhanced at least 4-fold. The identification of the positive 
cluster-situated regulators, OlmRI and OlmRII, paves the way for the transcriptional analysis of oligomycin biosynthesis and for 
the enhancement of oligomycin and avermectin production through regulator engineering. 
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Streptomycetes are Gram-positive soil bacteria that undergo 
morphological differentiations from substrate mycelia to 
aerial hyphae and chains of spores, and have an amazing 
ability to produce a great variety of valuable biologically 
active secondary metabolites, including hundreds of antibio- 
tics [1]. Antibiotics are usually produced during the late 
growth phase, and the coordinated expression of all the 
genes in an antibiotic biosynthetic gene cluster is tightly 
regulated in response to environmental conditions through a 
complex regulatory network [2]. 
The regulatory hierarchies employed by some repre-
sentative biosynthetic pathways have been elucidated, and a 
great number of regulatory genes involved in antibiotic 
production and morphological differentiation have been 
identified [3]. These genes take part in the regulation at dif-
ferent levels to respond to various external environmental 
changes and to the internal growth-phase transition. Some 
pleiotropic regulators execute global functions not only in 
secondary metabolism, but also in morphological differenti-
ation [4]. bldA, encoding a tRNA recognizing the rare leu-
cine codon UUA, is such a regulator. Mutation of bldA 
causes loss of aerial hyphae and of actinorhodin and un-
decylprodigiosin production [5–7]. Other important regula-
tory cascades are switched on by hormone-like molecules, 
such as the A-factor of S. griseus [8] or γ-butyrolactone in S. 
virginiae [9,10]. In S. griseus, A-factor binds to the A-factor 
receptor protein, ArpA, and initiates the transcription of 
adpA by dissociating the DNA-bound ArpA from the adpA 
promoter. AdpA then plays a central regulatory role in 
morphological development and secondary metabolism 
pathways by binding the transcriptional start sites of target 
genes and recruiting RNA polymerase to the promoter re-
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gions. In contrast, pathway-specific regulators only affect 
the transcription of a single antibiotic biosynthetic pathway, 
within which the genes are clustered. However, cluster- 
situated regulators, which are considered to be path-
way-specific, have also been shown to influence colony 
development [11]. 
Some well-known pathway-specific regulators situated in 
Type I polyketide synthase gene clusters belong to a novel 
LAL family (large ATP-binding regulators of the LuxR 
family) of activators [12]. They are large proteins that fea-
ture an N-terminal ATP/GTP-binding domain containing 
the Walker A and B motifs [13], and a C-terminal LuxR 
family helix-turn-helix (HTH) DNA-binding domain [14]. 
Examples of LAL transcriptional activators include PikD, 
required for pikromycin production by S. venezuelae [15], 
NysRI and NysRIII for nystatin biosynthesis in S. noursei 
[16], GdmRI and GdmRII for geldanamycin biosynthesis in 
S. hygroscopicus 17997 [17], and PimR for pimaricin bio-
synthesis in S. natalensis [18]. In particular, the LAL family 
regulator, AveR, is not only the key pathway-specific acti-
vator for avermectin biosynthesis but also negatively affects 
oligomycin production by down-regulating olmRI and 
olmRII transcription [19]. 
Oligomycins are a group of 26 macrolides that exhibit 
antifungal, antitumor and nematocidal activities [20–22]. 
They act as inhibitors of mitochondrial F1F0-ATPase lead-
ing to ATP depletion [23]. They can induce apoptosis in a 
variety of cell types, make cells more susceptible to cell 
death and can also cause a switch in the death mode from 
apoptosis to necrosis [24,25]. Recently, much research has 
focused on the potent anti-cancer activity of oligomycin 
[22,26,27]. The genome of S. avermitilis ATCC 31267, has 
been sequenced and contains more than 20 secondary me-
tabolite biosynthetic clusters [28]. Oligomycin A and aver-
mectin are the two main antibiotics synthesized by S. aver-
mitilis ATCC 31267 [29]. The oligomycin biosynthetic gene 
cluster extends to about 90 kb, including seven long open 
reading frames (ORFs) encoding multifunctional Type I 
polyketide synthases (PKSs) (Figure 1 from [30]). 
Genes olmRI (GI15823972) and olmRII (GI15823973) of 
S. avermitilis ATCC 31272, located upstream of the first 
PKS gene olmA1, were predicted to be LuxR-family regu-
lators. Through gene inactivation and complementation fol-
lowed by transcriptional analysis, we describe here the in-
volvement of olmRI and olmRII in oligomycin biosynthesis 
and their influence on avermectin production. 
1  Materials and methods 
1.1  Bacterial strains, media, growth conditions, DNA 
manipulation and sequence analysis 
All strains and plasmids used in this study are listed in Ta-
ble S1. Culture and standard bacteriological methods were 
performed as described by Sambrook et al. [31] and Kieser 
et al. [32]. According to refs. [33,34], the wild-type strain, S. 
avermitilis ATCC 31272, represents a lyophilized culture 
obtained by ultraviolet irradiation of S. avermitilis ATCC 
31267. The avermectin and oligomycin production, and the 
DNA sequence in the oligomycin cluster, were confirmed in 
this study to be consistent between the two strains. E. coli 
strains were grown at 37°C in Luria-Bertani medium. S. 
avermitilis ATCC 31272 and its mutants were grown at 
30°C on SFM [32] agar for oligomycin fermentation and for 
conjugation with E. coli ET12567/pUZ8002. YD agar [35] 
was used for sporulation, and TSBY liquid medium [32] 
supplemented with 10.3% (w/v) sucrose was used for myce-
lial growth. For Streptomyces, apramycin and thiostrepton 
were respectively used at 30 and 20 µg/mL in agar plates 
and at 15 and 10 µg/mL in liquid medium. 
General techniques for DNA manipulation were used as 
described in refs. [31,32]. Synthesis of oligonucleotide pri-
mers and DNA sequencing of PCR products were per-
formed by Invitrogen Biotechnology (China). Restriction 
digestions were carried out according to the protocols for 
the enzymes (Fermentas Inc., Canada). Analyses of amino 
acid sequences were performed using Blastp and ClustalW, 
and Pfam at http://pfam.janelia.org/ [36].  
1.2  Inactivation of olmRI and olmRII and complemen-
tation of the mutants 
Fragments (7.1–7.3 kb) were recovered from BamH I-  
digested total genomic DNA separated by agarose gel elec-
trophoresis, and cloned into pBluescript SK(+). After 
screening clones by Pvu II and Xho I digestion, a plasmid 
containing the 7266-bp olmRI-olmRII fragment was con-
firmed and named pJTU1714. The fragment was then 
 
 
Figure 1  Oligomycin biosynthetic gene cluster of S. avermitilis. Arrows indicate ORFs and the orientation of transcription. RI and RII (black arrows, 
olmRI and olmRII), LAL-family regulators; A1–A7 (blank arrow boxes, olmA1–olmA7), type I polyketide synthases. The grey arrows indicate the 
post-modification genes: mcmA, methylmalonyl-CoA mutase; pptA, phosphopantetheinyl transferase; simX, simX4 homolog; C (olmC), thioesterase; B 
(olmB), cytochrome P450; OII (olmOII), hypothetical protein; ccrA, crotonyl-CoA reductase; hbdA, 3-hydroxyacyl-CoA dehydrogenase.   
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BamH I-digested and transferred to pJTU412 to generate 
plasmid pJTU1715. To inactivate olmRI and olmRII, two 
aac(3)IV-oriT cassettes were amplified with the template 
pIJ773, using the primers olmRI-tgtP1 & P2, and olmRII- 
tgtP3 & P4 respectively (Table S2). They were then sepa-
rately introduced into E. coli BW25113/pIJ790/ pJTU1715 
by electroporation and recombined with pJTU1715 under 
temperature pressure [37] to generate the apramycin-   
resistant disruptants, pJTU1710 for ∆olmRI and pJTU1727 
for ∆olmRII. pJTU1710 and pJTU1727 were individually 
conjugated into S. avermitilis ATCC 31272 as described 
[32]. Apramycin-resistant thiostrepton-sensitive (AmR TsrS) 
double-crossover exconjugants YQ6 (∆olmRI) and YQ18 
(∆olmRII) were selected and confirmed by PCR with pri-
mers olmRI-test-P1 & P2 and olmRII-test-P3 & P4, respec-
tively (Table S2).  
For complementation, the plasmid pJTU1739 was con-
structed by inserting the 7266-bp fragment from pJTU1714 
into the BamH I-digested pIB139-derived vector, pJTU824 
(Table S1). pJTU1739 was introduced through conjugation 
into both of the mutants. YQ6: pJTU1739 and YQ18: 
pJTU1739 were selected by an AmR TsrR phenotype. 
1.3  Oligomycin and avermectin production assay 
Thawed suspensions of S. avermitilis ATCC 31272 and its 
derivatives were inoculated into 10 mL TSBY liquid me-
dium and grown at 30°C for 18 h to produce seed cultures. 
After detecting the wet weight of mycelia, the same 
amounts of seed cultures were grown on two SFM agar 
plates (40 mL melted medium spread to 56.5 cm2) at 30°C 
for 72 h for antibiotic production. The solid fermentation cul- 
tures were extracted twice for 8 h with two volumes of meth- 
anol. The methanol was evaporated and crude extracts were 
re-dissolved in 1 mL of methanol, passed through 0.22 µm 
nylon filters, and analyzed using an Agilent 1100 series 
LC/MSD Trap system using a ZORBAX Extend-C18 col-
umn (5 µm, 2.1 mm × 150 mm, Agilent, USA). Eluent A 
was Milli-Q (Millipore, USA) deionized water with 0.2% 
formic acid, and eluent B was acetonitrile. The LC was 
monitored at 230 nm and the flow rate was at 0.27 mL min–1 
using a gradient mobile phase starting with 60% B (v/v) and 
ending with 80% B for 15 min, followed by the isocratic 
mobile phase containing 80% B for 2 min, and finally by an 
increasing gradient phase ending with 90% B for 10 min. 
Oligomycin A from S. diastatochromogenes (Sigma-   
Aldrich Corp., Saint Louis, MO, USA) was used as the 
standard with a retention time of 15.3 min.  
1.4  Isolation of total RNA and gene expression analysis 
by quantitative real-time reverse transcriptase PCR 
(qPCR) 
For RNA isolation, S. avermitilis was grown for 3–4 d at 
30°C on SFM agar plates covered with cellophane sheets. 
Mycelia were scraped from the cellophane and disrupted in 
a Precellys Homogenizer (5500 × g, 1 × 30 s; Peqlab, Ger-
many) with glass beads (150–212 µm, Sigma). RNA was 
isolated with the total RNA Isolation Kit from SBS 
Genetech and treated with DNase I (RNAase-free, Fermen-
tas) to eliminate genomic DNA. 
RNA (3 µg) was used to generate cDNA using Re-
vertAid™ H Minus Reverse Transcriptase and Random 
Hexamer Primer (Fermentas) in 20-µL reactions, as de-
scribed in the manufacturer’s protocol. The synthesized 
cDNA (0.6 µL) was used as template for each reaction using 
the primers listed in Table S3. The sigma factor gene hrdB 
and the 16S rRNA gene were used as references and the 
primers were designed according to the 16S rRNA gene of S. 
lividans (X86354.1) and the hrdB gene of S. coelicolor 
(X52983.1), respectively. The primers for the target genes 
within the oligomycin cluster were designed to match the 
sequence of the S. avermitilis oligomycin biosynthetic gene 
cluster (AB070940.1, GI15823967). The qPCR reaction 
mixtures were prepared according to the protocol of Maxi-
ma® SYBR Green/ROX qPCR Master Mix (Fermentas). 
The qPCR assays were carried out in triplicate using the 
Applied Biosystems 7500 Fast Real-Time PCR System 
(Applied Biosystems Inc., USA) and then repeated 3 times 
with RNA isolated from independent batches. For a given 
target gene, the relative transcript copy number was the ra-
tio of its transcribed copies in mutant samples to its copies 
in the wild-type control. The ratio was calculated using the 
comparative Ct method with the formula 2
–∆∆Ct (∆∆Ct=  
∆Ct sample (target–reference) – ∆Ct control (target–reference)) [38]. All the 
key genes involved in oligomycin biosynthesis were ana-
lyzed. For each gene, the transcript copy number in the con-
trol wild-type strain was assigned a value of 1.0. A value 
higher than 2, suggested that the transcription of a target gene 
was distinctly activated or increased in the mutant. A value 
lower than 0.5 showed decreased or depressed transcription. 
2  Results and discussion 
2.1  In silico analysis of regulatory genes olmRI and 
olmRII 
Two putative regulatory genes, olmRI and olmRII, are lo-
cated upstream of olmA1, the first Type I PKS gene of the 
oligomycin biosynthesis pathway in S. avermitilis ATCC 
31272 [30]. Blastp analysis revealed that OlmRI (931 amino 
acids) and OlmRII (943 amino acids) share 38% identity, 
and are putative members of the LAL family (large 
ATP-binding regulators of the LuxR family) of transcrip-
tional activators [12]. Multiple alignments of LAL regula-
tors in the polyketide biosynthesis pathway revealed con-
served motifs that are also contained in OlmRI and OlmRII 
(Figure 2(a)). Walker A and B motifs are present at the N 
termini (Figure 2(b)) and LuxR-type HTH DNA binding 
motifs [14] are located at the C termini (Figure 2(c)). Close 
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to the HTH motifs are tetratricopeptide repeats (TPR) [39] 
at amino acid residues 615–834 in OlmRI and at 687–821 in 
OlmRII (Figure 2(a)). 
The Walker A and B motifs of OlmRI and OlmRII are 
characteristic of the triphosphate-binding domain of a large 
family of ATPases associated with diverse cellular activities. 
The two regulators were therefore proposed to hydrolyze 
NTP to activate oligomycin biosynthesis. Interestingly, 
Walker A motifs in OlmRI (aa 32–39) and OlmRII (aa 
17–24) have a truncated core motif GXGK(R)T(S), com-
pared to the consensus ATP-binding sequence, GXXG- 
XGKT [13]. The native S32OlmRI and A17OlmRII are different 
from the highly conserved glycine residue of other 
well-known Walker A motifs (indicated by a grey circle in 
Figure 2(b)). This reveals the diversity of the conserved 
sequences of the functional Walker A core motifs. The two 
regulators also have TPR domains implicating pro-
tein-protein interactions and the C-terminal LuxR-family 
DNA-binding helix-turn-helix domains. The known LuxR- 
family proteins, such as NysRI, NysRIII and PimR, can 
activate the biosynthesis of macrocyclic lactones. It was 
thus expected that inactivation of olmRI or olmRII would 
reduce or abolish oligomycin production by reducing the 
transcription of the cognate genes, which specify the en-
zymes involved in oligomycin biosynthesis.  
2.2  OlmRI is essential for oligomycin production 
To ascertain the involvement of olmRI in oligomycin bio-
synthesis, 300 bp of the coding region of olmRI was re-
placed by an aac(3)IV-oriT cassette using Redirect Technol-
ogy [37] (Figure 3(a)). Six apramycin-resistant and thiostrep-
ton-sensitive (AmR TsrS) mutants were confirmed by PCR 
amplification using primers olmRI-test-P1 and P2 and named 
as YQ6. The wild type gave a 1.16-kb amplified fragment, 
whereas YQ6 produced a 2.29-kb amplicon (Figure 3(b)).  
By comparing the size and morphological features of the 
single colonies on MM and SFM agar, the growth rate and 
morphology of wild type and YQ6 were exactly alike. We 
determined oligomycin yields of the wild type and mutant 
after 120 h of growth on SFM plates at 30°C when oligo-
mycin production was maximal. In two independent mu-
tants, HPLC profiles did not show any detectable peak cor-
responding to oligomycin (Figure 3(c)). Complemented 
with the plasmid pJTU1739, the oligomycin productivity of 
YQ6 was restored to about 10% of the wild-type level. 
Therefore, olmRI was found to execute positive control on 
oligomycin biosynthesis.  
2.3  Inactivation of olmRII abolished oligomycin pro-
duction 
Using a similar strategy as above, a 2040-bp internal region 
of olmRII was replaced by the aac(3)IV-oriT cassette (Fig-
ure 4(a)). Nine AmR TsrS mutants were verified by PCR  
 
Figure 2  Structures and alignment of the OlmRI and OlmRII regulators. 
(a) Conserved motifs in OlmRI and OlmRII. WA and WB, Walker A and 
B NTP binding motifs; TPR, tetratricopeptide repeats; HTHLuxR, 
LuxR-family HTH DNA-binding domains. (b) Alignment of the Walker A 
and B motifs from proteins resembling OlmRI and OlmRII. The circle 
indicates the conserved glycine residue that is divergent in OlmRI and 
OlmRII. The stars and spots indicate highly conserved amino acid residues. 
The aligned proteins include the known and putative LuxR-type regulators 
from various streptomyces sources: FkbN from S. hygroscopicus subsp. 
ascomyceticus, FscRIV from Streptomyecs sp. FR-008, GdmRI and 
GdmRII from S. hygroscopicus 17997, NbmM from S. narbonensis, 
NlmRI from S. nanchangensis, NysRI and NysRIII from S. noursei, PikD 
from S. venezuelae and RapH from S. cinnamonensis. (c) Alignment of 
LuxR-type HTH DNA-binding motifs.  
amplification with the primers olmRII-test-P3 & P4 and 
named YQ18 (Figure 4(b)).  
On MM and SFM agar plates, YQ18 showed a similar 
growth rate and morphology to the wild type. Similar to the 
∆olmRI mutant YQ6, HPLC assays showed no detectable 
peak corresponding to oligomycin in YQ18 (Figure 4(c)). 
pJTU1739 complementation of YQ18 also restored oligo-
mycin biosynthesis, but only up to 10% of the wild-type 
level. Therefore, OlmRII was also identified as an activator 
of the LAL regulator family for oligomycin biosynthesis. 
Moreover, the lack of oligomycin productivity in both 
olmRI and olmRII mutants of S. avermitilis ATCC 31267 
was also mentioned as unpublished data, without any ex-
perimental details, by Guo et al. [19].  
2.4  Transcriptional analysis of oligomycin biosynthetic 
genes in olmRI and olmRII mutants 
The transcription of all the key biosynthetic genes in the 
oligomycin cluster was analyzed by quantitative real-time 
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Figure 3  Inactivation of olmRI by gene replacement. (a) The strategy of generating the olmRI mutant YQ6 in S. avermitilis by replacing the 300-bp internal 
part of olmRI with the apramycin resistance gene aac(3)IV. (b) The desired mutants were confirmed by PCR analysis using primers olmRI-test P1 & P2 
(angled arrows in (a)). (c) HPLC assay of oligomycin production. Top, extract of the wild-type ATCC31272; middle, extract from YQ6; bottom, the extract 
of YQ6: pJTU1739. All the other peaks represent avermectins produced by S. avermitilis.  
 
Figure 4  Inactivation of olmRII. (a) The strategy of generating olmRII mutant YQ18 in S. avermitilis. (b) The desired mutants were confirmed by PCR 
analysis using primers olmRI-test P3 & P4 (angled arrows in (a)). (c) HPLC assay of oligomycin production. Top, extract of the wild-type ATCC31272; 
middle, extract from YQ18; bottom, the extract of YQ18: pJTU1739. All the other peaks represent avermectins.  
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RT-PCR. Total RNA was isolated from the wild type, 
olmRI mutant YQ6 strains and olmRII mutant YQ18 strains 
grown for 120 h on SFM agar covered with cellophane. The 
selected key genes included PKS genes, olmA1-olmA7, cy-
tochrome P450 gene, olmB, the post-modification genes, 
olmOI, ccrA and hbdA, and the thioesterase gene, olmC. 
Moreover, hrdB, encoding the constitutive vegetative sigma 
factor and 16S rRNA gene were used as internal references. 
The quantitative PCR primers were specifically designed 
within the first 1 kb of each gene. The primers, qolmRI fw-rv 
and qolmRII fw-rv (inset in Figure 5), were designed in the 
regions upstream of their corresponding inserted cassettes to 
assess the possibility of interplay between the two regulators. 
Figure 5 illustrates the general influence on the oligomy-
cin cluster by the disruption of olmRI and olmRII. The 
olmRI remnant in YQ6 was transcribed to a similar extent as 
in the wild type. Similarly, the remnant of olmRII was tran-
scribed at a slightly higher level than in the wild type (value 
1.5–1.8). These results indicate that these two regulators did 
not execute auto-regulation on themselves; compared with 
the wild type, the transcription ratios of olmRI in YQ18 and 
of olmRII in YQ6 were approximately 1.2 and 1.1, respec-
tively. This revealed no interplay between the two tandem 
LAL regulators.  
Obviously, in YQ6, inactivation of olmRI caused a sharp 
reduction in the transcription of all the PKS and post-   
modification genes. The expression of the PKS genes, olmC 
and olmA1–A7, located downstream and in the same orien-
tation as the regulatory genes, was reduced to 20%–30% of 
the wild type. Expression of the genes located in the reverse 
orientation, olmA4-olmB, olmOI-ccrA, but not hbdA, was 
severely declined to 2% of wild type levels. In short, OlmRI 
is a crucial positive transcriptional regulator controlling 
almost the whole oligomycin biosynthetic gene cluster. 
In contrast, compared to the wild type, inactivation of 
olmRII in YQ18 exerted different effects on olmC and  
olmA1–A7 transcription: olmC was expressed at almost wild 
type levels; olmA1, the first ORF encoding the polyketide 
skeleton, had increased its transcription more than 2-fold; 
the transcription of olmA2–A7 was reduced to approximately 
50%. These observations indicate that when OlmRII is dis-
rupted, OlmRI exerts very weak activation on the first four 
genes and strong positive control on the initial PKS genes. 
Meanwhile, the transcription of the reverse-direction PKS 
genes was nearly absent in YQ18, as in YQ6. This indicated 
that OlmRII was also a key positive transcriptional regulator 
of the reverse-direction genes in the oligomycin cluster.  
Different from other homologues, structurally similar 
OlmRI and OlmRII are both indispensable for oligomycin 
biosynthesis. Bioinformatic prediction reveals a putative 
protein-interacting TPR motif in OlmRI and OlmRII. This 
motif is capable of forming homodimers or heterodimers to 
activate the transcription of genes essential for oligomycin 
biosynthesis. Because the transcription of A1 increased and 
decreased with the respective disruption of RII and RI, RI is 
demonstrated to form a homodimer to activate the first PKS 
gene, A1. For the rest of the genes whose transcription lev-
els were severely impaired in both YQ6 and YQ18, a het-
erodimer of OlmRI and OlmRII is required to function in 
the activation of gene transcription. Oligomycin and its de-
rivatives are potent candidates for cancer therapy. Research 
on the positive regulators OlmRI and OlmRII may shed 
light on the over-production of this candidate compound. 
2.5  Enhanced avermectin production in both mutants 
Streptomyces avermitilis produces a series of avermectin 
analogues, including A2a, B1a, A1b and A1a (Figure 6(a)). 
 
 
Figure 5  Transcriptional analysis of the oligomycin biosynthetic cluster using real-time RT-PCR. The histograms represent the individual target gene’s 
transcriptional change as the ratio of the expression level in the mutants to that in the wild-type strain. Value of 1.0 (the bold line) indicates, for a certain 
target gene, that the mutant transcribes the same amount of mRNA as the wild type. Error bars were calculated from three independent experiments each 
with duplicates to validate the reproducibility. Solid bars, YQ6; white bars, YQ18. The inset shows the binding sites of the primers in olmRI and olmRII used 
for the quantitative real-time PCR, the solid arrow lines indicate primers qolmRI fw-rv and the dotted arrow lines indicate primers qolmRII fw-rv. The 
striped boxes marked the position of the replaced region in the ORFs.  
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Figure 6  The avermectin production in S. avermitilis and its mutants. (a) 
HPLC analysis of oligomycin and the series of avermectins in wild-type S. 
avermitilis ATCC31272. A2a, B1a, A1b and A1a are the main components 
of the avermectins. OLM refers to the peak representing oligomycin. Cor-
responding to (b), A2a is marked with grey filled circles and A1b with 
hollow triangles. (b) The variation in antibiotic production in wild type and 
mutants. 
In both of the LuxR-like regulator mutants, the production 
of avermectin was obviously enhanced. Component A2a 
was increased 1.5-fold in the mutants and component A1a 
was increased 2-fold (Figure 6(b)). However, further quan-
titative assays confirmed that aveR and aveA3, the known 
crucial regulatory and structural genes of avermectin bio-
synthesis, were transcribed at wild type levels (data not 
shown). Thus, OlmRI and OlmRII are cluster-situated spe-
cific activators of oligomycin biosynthesis. The over-  
production of avermectins in the mutants may be the result 
of increased metabolic flux towards avermectins while the 
oligomycin production was switched off. 
3  Conclusion 
Using gene inactivation and complementation in S. avermit-
ilis we have identified two positive cluster-situated regula- 
tors for oligomycin biosynthesis that show typical structural 
features of LuxR-type regulators, including an N-terminal 
ATP/GTP-binding domain and a C-terminal HTH DNA- 
binding domain. As detected by quantitative real-time RT- 
PCR, the transcription of genes in the oligomycin biosyn-
thetic cluster was altered to different extents in the olmRI or 
olmRII mutants, suggesting similar but different regulatory 
mechanisms for OlmRI and OlmRII. Moreover, even 
though olmRI and olmRII share high similarity and are lo-
cated close to one another, the effect of one mutant on the 
transcription of a particular gene was not observed in the 
other mutant. Meanwhile, disruption of the activator genes 
olmRI and/or olmRII unexpectedly enhanced the production 
of avermectin A1a and A2a components. This not only pro-
vides understanding of the competitive utilization of sub-
strates in Streptomyces avermitilis, but also provides a new 
strategy to enhance the productivity of antibiotics of interest. 
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